Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.

Inclusion Criteria:

• Age ≥18 years, male or female.
• High-risk pulmonary nodule/tumor maximum diameter ≤3 cm.
• Lesion judged suitable for bronchial navigation-guided diagnosis and treatment.
• Ineligible for surgery or refuses surgery/radiotherapy; agrees to primary ablation therapy; provides written informed consent.

Exclusion Criteria:

• Diffuse bilateral lung lesions unresponsive to ablation.
• Contraindication to bronchoscopy or inability to tolerate/cooperate with bronchoscopy.
• Severe bleeding tendency or irreversible coagulopathy (PT >18 s, PTA <40%).Platelet count <70×10⁹/L; anticoagulant/antiplatelet therapy discontinued <1 week before ablation (except prophylactic low-molecular-weight heparin).
• Severe pulmonary impairment (maximal voluntary ventilation <40%).
• Other metastatic tumors with widespread metastasis; life expectancy <3 months.
• Poor general condition: widespread metastasis, severe infection, high fever, infectious/radiation inflammation around the lesion, obvious cachexia, severe organ dysfunction, severe anemia, uncorrectable metabolic/nutritional disorders.
• Eastern Cooperative Oncology Group (ECOG) performance status >2.
• Target lesion received radiotherapy within the past 6 months.
• Active hepatitis B, active hepatitis C, known HIV-1/2 antibody positivity, or other active infections judged by the investigator to interfere with treatment.
• History of epilepsy, psychosis, or cognitive impairment.
• Pregnant/lactating females; males or females planning conception during the trial.
• Other conditions deemed inappropriate by the investigator.